News

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is scheduled to announce Q1 earnings results on Thursday, May 1st, before market open. The consensus EPS Estimate is -$3.79 and the consensus Revenue ...
Analysts expect Madrigal Pharmaceuticals to report an earnings per share (EPS) of $-3.83. The market awaits Madrigal Pharmaceuticals's announcement, with hopes high for news of surpassing estimates ...
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced six ...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.
Highlights,Cerity Partners LLC acquired a new position in Madrigal Pharmaceuticals during the fourth quarter.,Multiple financial entities, including Pitcairn Co. and Sanctuary Advisors LLC, increased ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), Exact ...
The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may ...
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced a key leadership transition as founder and Chief Medical Officer ...
Pharmaceutical bosses and the government are racing to stop Donald Trump from slapping tariffs on medicines in a move that would significantly impact Britain’s multibillion-pound industry.
Madrigal Pharmaceuticals (MDGL) announced that Rebecca Taub, M.D., the company’s founder, Chief Medical Officer, and President of Research ...
Join Matt Maley live this Wednesday at 6 PM ET to see how he’s trading it. MIRA Pharmaceuticals, Inc. MIRA on Wednesday released data demonstrating the efficacy of the oral ketamine analog ...